MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial…
MaaT PharmaOctober 7, 2025
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step…
MaaT PharmaJuly 28, 2025
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux Lyon, France, July 24,…
MaaT PharmaJuly 24, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaJuly 7, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease…
MaaT PharmaJuly 2, 2025
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France,…
MaaT PharmaJune 24, 2025
June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…
MaaT PharmaJune 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…
MaaT PharmaJune 13, 2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…
MaaT PharmaJune 2, 2025
